In pooled post hoc analyses of ULTIMATE I and II, ublituximab was associated with significant treatment benefit across multiple efficacy measures at Week 96 versus teriflunomide in participants who had not received prior DMT.

Massive Great Post !

$TGTX Three interesting posts . .

$TGTX @ern1in love the posts.

this should lift post 1/20 and really rocket come Q1/Q2 earnings.

$TGTX Absolute pleasure to see morale up and read all the positive posts again.

The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,

$HSDT $TGTX great post

$TGTX post aging like a fine wine🤌🏼

The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,

$RSLS 8s now from low 6s post this Morning up 35% so far

$RSLS posting this chart for its potential, it's looks better than MSGM

🚨 Post Market Movers🚨 $RSLS $MGTA $PCSA $JWN $WGS Stay tuned for more ideas!

300-500% Gainers post r/s.

That looks encouraging for biotechs post split.

Post R/S gonna see a big spike.

$RSLS Guys get excited and post how happy you are it's not falling.

Not a single one is over their post reverse split price.

$COSM had to post this, it’s just funny😂

$GNS $COSM $HUBC $ARDX Very interesting post 🤝🤔

Not a single one is over their post reverse split price.

Not a single one is over their post reverse split price.

$COSM Clearly this guy is liking his own post. 👇🏽🤡

$COSM Here it goes .. the funniest post today!

$COSM 100% since this post.

There is much to be excited about at COSM and that is all I post here.

Great Post!